Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTNDSF4)

• DTT Name: Proto-oncogene c-Met (MET) DTT Info
• Gene Name: MET

Molecule-Related Drug & Molecule List

5 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amivantamab	DMZ7AMY	Non-small-cell lung cancer	2C25	Approved	[1]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[2]
Capmatinib	DMYCXKL	Non-small-cell lung cancer	2C25.Y	Approved	[3]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Tepotinib	DMUQ0E8	Non-small-cell lung cancer	2C25	Approved	[5]

42 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beperminogene perplasmid	DM6RWBN	Critical limb ischemia	BD4Y	Phase 3	[6]
RG3638	DMTQJE0	Gastric adenocarcinoma	2B72	Phase 3	[7]
Savolitinib	DMALFKX	Renal cell carcinoma	2C90	Phase 3	[8]
Tivantinib	DMNVP8Q	Hepatocellular carcinoma	2C12.02	Phase 3	[9]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[7]
AMG 208	DMPQHOR	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
AMG 337	DMIOUEY	Clear cell sarcoma	2A60-2C35	Phase 2	[11]
APL-101	DMP0LST	Non-small-cell lung cancer	2C25	Phase 2	[12]
CMX-2043	DMPSCVY	Cardiac disease	BA00-BE2Z	Phase 2	[13]
Emibetuzumab	DMT4MKF	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]
HM-5016504	DMLQDBH	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
LY-2875358	DMQV1OU	Solid tumour/cancer	2A00-2F9Z	Phase 2	[15]
LY2801653	DM0KJDY	Biliary tract cancer	2C17	Phase 2	[16]
SAR-125844	DMJ34G6	Solid tumour/cancer	2A00-2F9Z	Phase 2	[17]
Telisotuzumab vedotin	DM8UCNK	Non-small-cell lung cancer	2C25.Y	Phase 2	[18]
XL880	DMHJTR2	Breast cancer	2C60-2C65	Phase 2	[19]
Anti-C-met CAR-T cells	DMV5H0S	Colorectal cancer	2B91.Z	Phase 1/2	[20]
BMS-777607	DMGM7QD	N. A.	N. A.	Phase 1/2	[21]
ChronSeal	DM90BUD	Fibrosis	GA14-GC01	Phase 1/2	[22]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[23]
Sym015	DM9B7Z5	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
ABBV-399	DMQGPRE	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
ABT-700	DMVLPRT	Advanced solid tumour	2A00-2F9Z	Phase 1	[24]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[25]
Autologous T Cells Expressing MET scFv CAR	DMZ763A	Melanoma	2C30	Phase 1	[26]
AZD9592	DMDPM67	Aggressive cancer	2A00-2F9Z	Phase 1	[27]
BPI-9016 M	DMNY0U5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[28]
C-Met/PD-L1 CAR-T Cell	DMHBNKP	Hepatocellular carcinoma	2C12.02	Phase 1	[29]
CBT-101	DMOTLN4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
E-7050	DMDOCNW	Head and neck cancer	2D42	Phase 1	[30]
EMD-1204831	DM38JZU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[31]
Hepapoietin	DMM7VOB	Liver disease	DB90-BD99	Phase 1	[32]
JNJ-38877605	DMDIPW8	Solid tumour/cancer	2A00-2F9Z	Phase 1	[33]
LY3164530	DM9RTXM	Advanced cancer	2A00-2F9Z	Phase 1	[34]
MK-8033	DMA1EDN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[35]
PF-4217903	DMU2A6D	Solid tumour/cancer	2A00-2F9Z	Phase 1	[36]
REGN5093	DM3720L	Non-small-cell lung cancer	2C25.Y	Phase 1	[37]
RXDX-106	DM6NVTR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[38]
SGX523	DM3RSMF	Solid tumour/cancer	2A00-2F9Z	Phase 1	[39]
TPX-0022	DMC2IJN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[40]
TR1801-ADC	DMGC2AT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[41]
XL092	DM3LRAC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[42]

2 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mteron-F1	DMCZW4Q	Mucositis	CA00	Preclinical	[43]
NPS-1034	DMOGRWB	Solid tumour/cancer	2A00-2F9Z	Preclinical	[44]

27 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine	DMR12KP	Discovery agent	N.A.	Investigative	[45]
1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine	DM8APLN	Discovery agent	N.A.	Investigative	[45]
1-benzyl-1H-pyrrolo[3,2-b]pyridine	DMEVSFY	Discovery agent	N.A.	Investigative	[45]
3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine	DMN1DWF	Discovery agent	N.A.	Investigative	[45]
ALD-805	DMQXO5G	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
ALD-806	DMWBKH1	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
AM7	DMYVQFN	Discovery agent	N.A.	Investigative	[46]
Anti-cMET mab	DM2X1SG	Discovery agent	N.A.	Investigative	[7]
APS-3010	DM8DOBG	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
BAY-85-3474	DMW625B	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[47]
CMET Avimer polypeptides	DM6PFG0	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
DP-3590	DMFZML9	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
GE-137	DMB813H	Discovery agent	N.A.	Investigative	[48]
HuMax-cMet	DM8AG5R	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
LA-480	DMP1V8Y	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
mab 224G11	DM1ICOW	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
PF-00614435	DMWL9CU	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
PHA-665752	DMCGX9U	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
PMID21123062C27	DMVPW1G	Discovery agent	N.A.	Investigative	[49]
PMID21967808CR-16	DMCOHKU	Discovery agent	N.A.	Investigative	[50]
PMID24210504C1o	DM4LEUT	Discovery agent	N.A.	Investigative	[51]
PRS-110	DMB923H	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
RP-1040	DMP2EDX	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
SU11274	DMASP9Z	Discovery agent	N.A.	Investigative	[52]
TP-801	DM4WTCE	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
YH013	DMQ0474	Aggressive cancer	2A00-2F9Z	Investigative	[53]

References

• [1] Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
• [2] Clinical pipeline report, company report or official report of Exelixis (2011).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [6] Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
• [10] A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30;6(21):18693-706.
• [11] J Clin Oncol 32:5s, 2014 (suppl; abstr 2508).
• [12] Clinical pipeline report, company report or official report of Apollomics.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Clinical pipeline report, company report or official report of Eli Lilly.
• [16] Clinical pipeline report, company report or official report of Eli Lilly.
• [17] The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther. 2015 Feb;14(2):384-94.
• [18] Clinical pipeline report, company report or official report of AbbVie.
• [19] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [20] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [21] Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607... J Med Chem. 2009 Mar 12;52(5):1251-4.
• [22] Clinical pipeline report, company report or official report of Kringle Pharma.
• [23] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [24] J Clin Oncol 32:5s, 2014 (suppl; abstr 2507).
• [25] Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
• [26] ClinicalTrials.gov (NCT03060356) Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
• [27] Clinical pipeline report, company report or official report of AstraZeneca
• [28] First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6.
• [29] ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
• [30] E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5.
• [31] 2012 ASCO Annual Meeting.
• [32] Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. Alimentary Pharmacology & Therapeutics Volume 16, Issue 2, pages 235-242, February 2002.
• [33] The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 2015 May 15;21(10):2297-304.
• [34] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [35] A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
• [36] Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47.
• [37] Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
• [38] National Cancer Institute Drug Dictionary (drug name RXDX106).
• [39] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [40] Clinical pipeline report, company report or official report of Turning Point Therapeutics.
• [41] TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68.
• [42] Clinical pipeline report, company report or official report of Exelixis.
• [43] Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
• [44] NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants. Invest New Drugs. 2014 Jun;32(3):389-99.
• [45] Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4.
• [46] c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 2008 Feb 1;283(5):2675-83.
• [47] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [48] Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med. 2015 Aug;21(8):955-61.
• [49] Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):164-7.
• [50] Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84.
• [51] Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6711-6.
• [52] Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther. 2003 Nov;2(11):1085-92.
• [53] Clinical pipeline report, company report or official report of Biocytogen